AstraZeneca PLC (ETR: ZEG)

Market Cap	191.90B
Revenue (ttm)	45.91B
Net Income (ttm)	5.82B
Shares Out	n/a
EPS (ttm)	3.72
PE Ratio	32.95
Forward PE	n/a
Dividend	2.72 (2.19%)
Ex-Dividend Date	Aug 8, 2024

Volume	12,196
Open	125.35
Previous Close	126.00
Day's Range	123.80 - 125.90
52-Week Range	112.35 - 158.20
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 89,900
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ZEG

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial numbers in USD